Tango Therapeutics Inc Stock Price, News & Analysis

Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in a Phase 1/2 trial combining its TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.

The study aims to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. TNG462, a MTA-cooperative PRMT5 inhibitor, is also being studied as monotherapy with data expected in H2 2025. The monotherapy results will inform a registrational trial in pancreatic cancer and advance the lung cancer development plan.

Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Barbara Weber, M.D., will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for June 10 at 3:20-3:55 PM ET. Investors can access the live webcast through the "Events & Presentations" section on the company's website, and a replay will be available for 90 days following the event.

Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in its Phase 1/2 clinical trial of TNG456, a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor. The trial focuses on patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). The study (NCT06810544) will evaluate TNG456's safety, pharmacokinetics, pharmacodynamics, and antitumor activity both as monotherapy and in combination with abemaciclib.

The trial's significance is highlighted by the current poor prognosis for GBM patients, who face a five-year survival rate below 10%. Notably, 45% of GBM cases are MTAP-deleted, presenting a substantial potential patient population. Preclinical studies have shown promising results regarding TNG456's potency, MTAP-selectivity, and brain exposure, suggesting potential efficacy in GBM treatment.

Tango Therapeutics (NASDAQ: TNGX) reported Q1 2025 financial results and pipeline updates. The company's lead candidate TNG462, a PRMT5 inhibitor, is progressing with data updates expected in 2H 2025, focusing on pancreatic and lung cancer. A combination trial with Revolution Medicines' RAS(ON) inhibitors is set to begin in Q2 2025. The company reported $216.7 million in cash, extending runway into Q1 2027 through reduced preclinical spending. Q1 2025 financials showed collaboration revenue of $5.4 million (down from $6.5M in Q1 2024), R&D expenses of $36.4 million (down from $38.1M), and a net loss of $39.9 million ($0.36 per share). Other pipeline developments include TNG456 for glioblastoma, TNG260 showing proof-of-mechanism in NSCLC trials, and TNG961, a novel HBS1L molecular glue degrader for FOCAD-deleted cancers.

Tango Therapeutics (NASDAQ: TNGX) has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, before U.S. financial markets open. The company has stated that it will not host a conference call to discuss the results.

Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of five abstracts for poster presentation at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase preclinical data focusing on their PRMT5 inhibitor programs, particularly TNG456 and TNG462, designed for treating MTAP-deleted cancers.

The research highlights include evaluation of CNS drug penetration, brain-penetrant capabilities, combination therapy potential with KRAS-inhibitors, and analysis of MTAP truncations impact. Additionally, the company will present findings on tumor regression in FOCAD-deleted cancers through HBS1L/PELO complex disruption.

According to Dr. Adam Crystal, President of Research and Development, the data demonstrates the potential of their molecules as standalone treatments and combination partners in MTAP-deleted cancers, suggesting future development opportunities.

Tango Therapeutics (NASDAQ: TNGX) has reported its Q4 and full year 2024 financial results with several key developments. The FDA granted Orphan Drug Designation to TNG462 for pancreatic cancer treatment and cleared the IND application for TNG456, their brain-penetrant PRMT5 inhibitor.

The company established a clinical collaboration with Eli Lilly to evaluate TNG456 in combination with Verzenio. Early data for TNG462 showed durable clinical responses across multiple cancer types, including partial responses in pancreatic and lung cancer.

Financial highlights include:

• Cash position of $257.9M as of December 31, 2024
• Q4 2024 collaboration revenue of $4.1M vs $5.4M in Q4 2023
• Net loss of $37.7M ($0.35 per share) in Q4 2024
• Full-year net loss of $130.3M ($1.19 per share)

The company's cash runway is expected to fund operations into Q3 2026.

Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in three major investment bank conferences in early 2025.

The company will participate in:

• The B Riley Precision Oncology & Radiopharma Conference in New York, featuring a panel discussion on 'Pushing Tumors Over the Edge with Synthetic Lethality' on February 28 at 9:00 AM ET
• The Leerink Global Healthcare Conference in Miami, hosting a fireside chat on March 12 at 2:20 PM ET
• The Barclays 27th Annual Global Healthcare Conference in Miami on March 13, available for one-on-one meetings

Webcasts will be available on the company's website under the 'Events & Presentations' tab, with replays archived for 90 days post-presentation.

Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in the upcoming Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:00 AM ET.

The event will be accessible through a live webcast, available at the provided link and through the company's website under the 'Events & Presentations' section of the Investors page. The presentation recording will remain available on Tango's website for 90 days following the event.